EU-PACT: Warfarin dose guided by genotype

Anticoagulation level in response to a fixed dose of warfarin is difficult to predict at the start of therapy. The CYP2C9 gene polymorphism (involved in the metabolism of warfarin) and VKORC1 (involved in the vitamin K cycle) with the age and the body surface are responsible for about 50% of the individual variability in dose.

This study was designed to test the hypothesis of a warfarin prescribing guided by genetic markers that may add therapeutic benefits. This was a multicenter, controlled study that included 455 patients with atrial fibrillation or venous thromboembolism who were randomized to warfarin prescribing according to genotype (n = 227) versus standard dose (n = 228). The primary endpoint was the percentage time in three months that patients were within a suitable range of RIN              (between 2 and 3). The percentage of time within target range was 67.4 % for the adjusted group by genotype versus 60.3 % for the standard group (p < 0.001).

Conclusion:

The administration of warfarin based on Pharmacogenetics was associated with a greater percentage of time within the target range of anticoagulation.

Article

4_munir_pirmohamed_slides
Munir Pirmohamed
2013-11-19

Original title: EU-PACT: A Randomized Trial Comparing Genotype-Guided Dosing of Warfarin to Standard Dosing: The EU Pharmacogenetics of Anticoagulant Therapy Warfarin Study

More articles by this author

COAG Trial: Dose of warfarin and Pharmacogenetics

Observational studies identified two genes that influence the dose of warfarin (CYP2C9 and VKORC1). The clinical utility of dose adjustment by genetics has been...

ERASE: Endovascular treatment plus exercise versus exercise alone to treat claudication

Initial therapy for intermittent claudication has been historically the gear train, however, especially in recent years; the number of peripheral angioplasties has increased, proving...

RADAR AF: High-frequency ablation versus pulmonary vein isolation to treat atrial fibrillation

Atrial fibrillation is initiated by focal triggers and maintained by an atrial substrate called fractioned complex of atrial electrograms. Isolating the pulmonary veins (triggers)...

ENGAGE AF-TIMI 48: Endoxaban versus warfarin in atrial fibrillation

The endoxaban is an oral direct inhibitor of factor Xa with a rapid onset of action and a half-life of 8-10 hours. Endoxaban efficacy...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...